Drug Type Bispecific antibody, Therapeutic radiopharmaceuticals |
Synonyms + [1] |
Mechanism Histamine succinyl glycine inhibitors(Histamine succinyl glycine inhibitors), MFN2 modulators(mitofusin 2 modulators), oxMIF inhibitors |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | AT | 25 May 2024 | |
Head and Neck Neoplasms | Preclinical | AT | 25 May 2024 | |
Pancreatic Cancer | Preclinical | AT | 25 May 2024 | |
Stomach Cancer | Preclinical | AT | 25 May 2024 |